Canaccord raised the firm’s price target on Generation Bio (GBIO) to $10 from $9 and keeps a Buy rating on the shares. The firm said the company update included 2 key announcements. First, it announced new NHP data that shows siRNA delivery to T cells via the company’s proprietary ctLNP platform; likely the first dataset of its kind. And also noted that it has developed siRNA candidates targeting LAT1 and VAV1, known targets in the autoimmune space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GBIO:
- Generation Bio Co. Warns Stakeholders of Persistent Business Risks in 2024 Report
- Generation Bio’s Promising siRNA Delivery and Financial Stability Justify Buy Rating Despite Workforce Reductions
- Wedbush downgrades Generation Bio as company seeks strategic alternatives
- Generation Bio downgraded to Neutral from Outperform at Wedbush
- Generation Bio Co. Reports Promising Data and Financial Results